Autophagosome-lysosome fusion machinery

The autophagosome-lysosome fusion machinery is a complex protein network that mediates the final step of macroautophagy, where the autophagosome merges with the lysosome to degrade its contents (Itakura et al., 2012, Nature). This process is orchestrated by a specific set of proteins, including the SNARE complex (Syntaxin 17, SNAP29, and VAMP8), the HOPS (homotypic fusion and vacuole protein sorting) tethering complex, and the small GTPase Rab7 (Jiang et al., 2014, PNAS; Diao et al., 2015, eLife). Biologically, this machinery is vital for maintaining cellular proteostasis by clearing damaged organelles and protein aggregates, and it plays a key role in nutrient recycling during periods of starvation (Mizushima, 2007, Genes & Dev). In disease, impaired fusion is a hallmark of neurodegenerative conditions like Alzheimer’s and Parkinson’s, where the failure to clear toxic proteins leads to neuronal dysfunction (Nixon, 2013, Nature Medicine). Conversely, in cancer, tumor cells often exploit this machinery to survive metabolic stress, making it a target for therapeutic inhibition (Mauthe et al., 2018, Autophagy). Pharmacological agents such as chloroquine and hydroxychloroquine are commonly used to block this process by increasing lysosomal pH, thereby preventing the fusion event and subsequent degradation (Mauthe et al., 2018, Autophagy). Experimental small molecules are also being developed to either enhance fusion in neurodegeneration or inhibit it more specifically in oncology (Moreau et al., 2014, Nature Communications).

Other names

Lysosome/autophagosome–lysosome fusion machineryAutophagosome-lysosome fusionMacroautophagy fusion machinerySTX17-SNAP29-VAMP8 complexLysosomal fusion machinery

Inhibition of lysosomal acidification or V-ATPase activity, which disrupts the environment necessary for autophagosome-lysosome fusion and enzymatic degradation (Mauthe et al., 2018, Autophagy).